Evidence map›Paper›PMID 35774109›Full record

ArticleComprehensive psychoneuroendocrinology2022

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time.

Gallen Triana-Baltzer, Maarten Timmers, Peter De Boer, Manja Schoene, Maura Furey, Cathy Bleys, Isabeau Vrancken, Randy Slemmon, Marc Ceusters, Luc van Nueten and 1 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Comprehensive psychoneuroendocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02475148 phase1completednot on this map

A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Subjects

TypeinterventionalSponsorJanssen-Cilag International NVRan2015 to 2015Enrolled76ConditionsHealthyArmsJNJ 54175446, Placebo, High fat/high Calorie Breakfast
NCT02933762 phase1completednot on this map

An Exploratory, Single-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Dose Pharmacodynamics Study in Healthy Subjects to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma

TypeinterventionalSponsorJanssen Research & Development, LLCRan2016 to 2016Enrolled25ConditionsHealthyArmsJNJ-54175446, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Gallen Triana-BaltzerJanssen Research & Development, LLC, San Diego, CA, USA.
Maarten TimmersJanssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Peter De BoerJanssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Manja SchoeneJanssen Research & Development, LLC, San Diego, CA, USA.
Maura FureyJanssen Research & Development, LLC, San Diego, CA, USA.
Cathy BleysJanssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Isabeau VranckenJanssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Randy SlemmonJanssen Research & Development, LLC, San Diego, CA, USA.
Marc CeustersJanssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Luc van NuetenJanssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Hartmuth KolbJanssen Research & Development, LLC, San Diego, CA, USA.
Janssen (Belgium) · BEJanssen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of putative biomarkers for neuropsychiatric disorders has produced a diverse list of analytes involved in inflammation, hypothalamic-pituitary-adrenal axis (HPA) regulation, growth factor and metabolic pathways. However, translation of these findings to accurate and robust assays has been stalled, affecting objective diagnoses, tracking relapse/remission, and prediction/monitoring of drug affect. Two important factors to control are the sample matrix (e.g. serum, plasma, saliva, or cerebrospinal fluid) and time of sample collection. Additionally, sample collection procedures may affect analyte level. In this study, a panel of 14 core neuropsychiatric biomarkers was measured in serum, plasma, saliva, and cerebrospinal fluid (CSF), all collected from 8 healthy volunteers at the same time. In a second cohort of 7 healthy volunteers, 6 analytes were measured in serum and CSF collected at 13 timepoints over a 24-h period after catheter placement. We found that many of the analytes were quantifiable in all sample types examined, but often at quite different concentrations and without correlation between the sample types. After catheter placement, a diurnal pattern was observed for cortisol and interleukin-6 in serum, and transient spikes were observed in interleukin-1β. In CSF, a chronic elevation of several cytokines was observed instead, perhaps due to the continuous sampling procedure. These findings enable more informed decision-making around sample type and collection time, which can be implemented in future biomarker studies. Clinicaltrialgov identifiers: NCT02933762, NCT02475148.

Indexed as

Diurnal patternNeuropsychiatric biomarkersNeuropsychiatric disorders

Identifiers

PMID35774109
PMCPMC9231640
OpenAlexW4205753961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.